Advanced Malignancies
Showing NaN - NaN of 9
Advanced Malignancies, Metastatic Cancer Trial in Worldwide (INCAGN01876, Nivolumab, Ipilimumab)
Completed
- Advanced Malignancies
- Metastatic Cancer
- INCAGN01876
- +2 more
-
Los Angeles, California
- +37 more
Dec 6, 2022
Recurrent Cancer, Metastatic Cancer, Advanced Malignancies Trial (INCAGN01876, retifanlimab)
Recruiting
- Recurrent Cancer
- +3 more
- INCAGN01876
- retifanlimab
-
Birmingham, Alabama
- +17 more
Dec 13, 2022
Advanced Malignancies Trial in United States (Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody)
Active, not recruiting
- Advanced Malignancies
- Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody
-
Santa Monica, California
- +13 more
Dec 12, 2021
Advanced Cancer, Advanced Malignancies Trial in Australia, Spain, United States (Cemiplimab, Hypofractionated radiotherapy,
Completed
- Advanced Cancer
- Advanced Malignancies
- Cemiplimab
- +7 more
-
Gilbert, Arizona
- +46 more
Jan 23, 2020
NSCLC, Lung Cancer, Advanced Malignancies Trial in La Jolla, Orange, Detroit (Brigatinib)
No longer available
- Non-small Cell Lung Cancer
- +3 more
-
La Jolla, California
- +2 more
Feb 5, 2018
Advanced Malignancies Trial in United States (MEDI0680 (AMP-514))
Completed
- Advanced Malignancies
- MEDI0680 (AMP-514)
-
New Haven, Connecticut
- +5 more
Oct 4, 2017
Advanced Malignancies Trial in United States (CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod)
Completed
- Advanced Malignancies
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC
- +3 more
-
New Haven, Connecticut
- +6 more
Jun 22, 2016
